Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. (Q46706721)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Chuah C

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Barnes DJ

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Corbin A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Deininger MW

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Melo JV

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 November 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

1896-1904

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16167056%20AND%20SRC:MED&resulttype=core&format=json

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Cell cycle targets of Ras/Raf signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Ras and Rho regulation of the cell cycle and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

7 January 2021

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

7 January 2021

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

7 January 2021

Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

7 January 2021

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

7 January 2021

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403949

7 January 2021